NextCure, Inc. (NXTC)
- Previous Close
1.2900 - Open
1.3000 - Bid 1.2800 x 100
- Ask 1.3700 x 100
- Day's Range
1.2900 - 1.4500 - 52 Week Range
0.9800 - 2.5700 - Volume
44,090 - Avg. Volume
286,819 - Market Cap (intraday)
38.088M - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2500 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
www.nextcure.comRecent News: NXTC
Performance Overview: NXTC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NXTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NXTC
Valuation Measures
Market Cap
35.99M
Enterprise Value
-65.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.03
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.08%
Return on Equity (ttm)
-44.49%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-62.72M
Diluted EPS (ttm)
-2.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
108.3M
Total Debt/Equity (mrq)
5.77%
Levered Free Cash Flow (ttm)
-33.96M